Sector News

Matchmaking investors pick Biogen, Pfizer as fave Allergan deal partners

August 18, 2015
Life sciences
Who should serial buyer Allergan pick up next? It’s the question on the minds of many industry watchers–including Evercore ISI analyst Umer Raffat, who polled investors last week. And while there are lots of possibilities floating around, his respondents seem to have a pair of potential deals in mind.
 
Both a buyout of multiple sclerosis drugmaker Biogen and a tie-up with pharma giant Pfizer are on investors’ radar, Raffat found, with each of the two companies picking up about 20% of their votes. Behind them was Shire with around 15%, followed by AbbVie, Vertex and Amgen. Baxalta, Celgene, Bristol-Myers Squibb and AstraZeneca trailed further behind, with the write-in option garnering 10% of responses, too.
 
That Biogen and Pfizer deals are on investors’ minds comes as no surprise, considering the buzz about both drugmakers in relation to Allergan. The Pfizer rumors are older; the New York company has been looking for a tax-inversion target ever since its proposal for U.K. rival AstraZeneca fell through, and many have suggested that Dublin-based Allergan would do the trick.
 
After all, Allergan is no stranger to “transformational” deals. Back when it was Actavis, it dropped $66 billion to buy Allergan, building up its brand stable and reimagining itself as a “growth pharma” that housed both brands and generics under one roof. But when Teva came calling earlier this summer, it turned right around and hived off its generics for $40.5 billion.
 
Biogen talk has been cropping up since that time, too, with the Teva sum settling Allergan’s M&A debt and opening the door for more dealmaking. The Massachusetts biotech has been struggling as of late, with lukewarm Alzheimer’s trial data and lagging sales of MS star Tecfidera triggering a selloff frenzy and making it a cheaper target.
 
Allergan CEO Brent Saunders hasn’t said a whole lot himself about who he’s got his eye on–aside from the fact that he spends “zero time” thinking about Pfizer, as he told the Financial Times last month. He offered some insights on the company’s Q2 earnings call, though, telling shareholders that he’s willing to look at drugmakers with slightly lower growth rates as long as the buys would be “highly accretive”–and cautioning investors not to look for another company-reshaping transaction until the Teva deal closes.
 
By Carly Helfand
 
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”